Dechra Pharmaceuticals PLC Director/PDMR Shareholding (4651Z)

TIDMDPH

RNS Number : 4651Z

Dechra Pharmaceuticals PLC

18 September 2020

18 September 2020

Dechra Pharmaceuticals PLC

Notification of Transactions by Persons Discharging Managerial Responsibilities

On 18 September 2020, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Person Discharging Managerial Responsibilities that he had completed a transfer of part of his beneficial interest in Dechra.

Ian Page, Executive Director, has transferred 2,000 ordinary shares in the Company to his son, David Page. Following these transactions, Ian Page will continue to retain a beneficial holding of 623,374 ordinary shares which represents 0.577% of the current issued share capital in the Company.

The Notification of Dealing Form set out below is provided in accordance with Article 19.3 of MAR.

Notification of Dealing Form:

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                                     Ian Page 
     ---------------------------------------  ---------------------------------- 
 2.   Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position/status                          Director 
     ---------------------------------------  ---------------------------------- 
 b)   Initial notification/amendment           Initial Notification 
     ---------------------------------------  ---------------------------------- 
 3.   Details of the Issuer 
     --------------------------------------------------------------------------- 
 a)   Name                                     Dechra Pharmaceuticals PLC 
     ---------------------------------------  ---------------------------------- 
 b)   LEI code                                 213800J4UVB5OWG8VX82 
     ---------------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     --------------------------------------------------------------------------- 
 a)   Description of the financial             Ordinary Shares of 1 pence each 
       instrument                               ISIN: GB0009633180 
       Identification code 
     ---------------------------------------  ---------------------------------- 
 b)   Nature of the transaction                Transfer of Shares 
     ---------------------------------------  ---------------------------------- 
 c)   Price(s) and volumes(s)                  Price(s)          Volume(s) 
                                                GBPN/A            2,000 
     ---------------------------------------  ----------------  ---------------- 
 d)        Aggregated information 
             *    Aggregate volume               2,000 
                                                 GBPN/A 
                                                 GBPN/A 
             *    Price 
 
 
             *    Total 
     ---------------------------------------  ---------------------------------- 
 e)   Date of the transaction                  18 September 2020 
     ---------------------------------------  ---------------------------------- 
 f)   Place of the transaction                 Outside a trading venue 
     ---------------------------------------  ---------------------------------- 
 
 
 Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive                Office: [phone] 
  Officer 
 Paul Sandland, Acting Chief              Office: [phone] 
  Financial Officer 
  e-mail: [e-mail] 
 
 TooleyStreet Communications 
  Ltd 
 Fiona Tooley, Director                   Office: [phone] 
  e-mail: [e-mail]           Mobile: [phone] 
---------------------------------------  ------------------------------ 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKKFBDDBKDQCD

(END) Dow Jones Newswires

September 18, 2020 07:16 ET (11:16 GMT)